Ultrasonic Center, Guizhou Medical University, Guiyang, China.
Hypertension Department, Guizhou Medical University, Guiyang, China.
Ann Palliat Med. 2022 Feb;11(2):684-694. doi: 10.21037/apm-21-3936.
Ultrasound cardiogram is commonly used in the diagnosis of cardiac hypertrophy from hypertension. This study aimed to investigate the correlation between the occurrence of cardiac hypertrophy from hypertension with the expression of autophagy-related protein 9A (ATG9a).
In this study, 168 patients with hypertension in the Guizhou Medical University from February 2020 to September 2021 were selected. The patients were divided into an experimental group (cardiac hypertrophy group) and a normal group according to the results of ultrasound cardiogram examination, and serum ATG9a levels in the two groups were detected. The association between ATG9a and cardiac hypertrophy from hypertension and the relationship between serum ATG9a and ultrasound cardiogram indicators were analyzed. And a receiver operating characteristic (ROC) curve was drawn to analyze the value of ATG9a in the diagnosis of cardiac hypertrophy from hypertension.
The results showed that there were no significant differences in age, diastolic blood pressure, hypertension course, body mass index (BMI), smoking history, and drinking history between the experimental and normal groups (P>0.05). Binary logistic regression analysis showed that compared with the normal control group, ATG9a increased significantly (P<0.05) and systolic blood pressure decreased significantly in the experimental group. The results showed that the area under the curve (AUC) of serum ATG9a was 0.736, the sensitivity was 76.54%, and the specificity was 78.42% in the diagnosis of cardiac hypertrophy from hypertension. Pearson correlation analysis showed that ATG9a was positively correlated with left ventricular posterior wall thickness (LVPWT) and interventricular septal thickness (IVST) in patients with cardiac hypertrophy from hypertension, and was negatively correlated with left ventricular ejection fraction (LVEF) (P<0.05).
Serum ATG9a may be involved in the formation of cardiac hypertrophy in hypertensive patients. Our results, which showed that serum ATG9a level increased in cardiac hypertrophy patients, were consistent with the clinical ultrasonic cardiogram diagnosis result, and ATG9a is expected to be a marker for early ultrasonic cardiogram diagnosis.
超声心动图常用于诊断高血压引起的心脏肥大。本研究旨在探讨高血压引起的心脏肥大与自噬相关蛋白 9A（ATG9a）表达的相关性。
本研究选取 2020 年 2 月至 2021 年 9 月在贵州医科大学就诊的 168 例高血压患者，根据超声心动图检查结果将患者分为实验组（心脏肥大组）和正常组，检测两组患者的血清 ATG9a 水平，分析 ATG9a 与高血压引起的心脏肥大的关系以及血清 ATG9a 与超声心动图指标的关系，并绘制受试者工作特征（ROC）曲线分析 ATG9a 对高血压引起的心脏肥大的诊断价值。
结果显示，实验组与正常组在年龄、舒张压、高血压病程、体质量指数（BMI）、吸烟史、饮酒史等方面比较差异均无统计学意义（P>0.05）。二元 logistic 回归分析显示，与正常对照组相比，实验组 ATG9a 明显升高（P<0.05），收缩压明显降低。结果显示，血清 ATG9a 诊断高血压引起的心脏肥大的曲线下面积（AUC）为 0.736，灵敏度为 76.54%，特异度为 78.42%。Pearson 相关性分析显示，高血压引起的心脏肥大患者血清 ATG9a 与左心室后壁厚度（LVPWT）和室间隔厚度（IVST）呈正相关，与左心室射血分数（LVEF）呈负相关（P<0.05）。
血清 ATG9a 可能参与了高血压患者心脏肥大的形成。我们的结果表明，心脏肥大患者的血清 ATG9a 水平升高，与临床超声心动图诊断结果一致，ATG9a 有望成为早期超声心动图诊断的标志物。
